Zizimin2: a novel, DOCK180-related Cdc42 guanine nucleotide exchange factor expressed predominantly in lymphocytes

被引：51

作者：

Nishikimi, A

Meller, N

Uekawa, N

Isobe, K

Schwartz, MA

Maruyama, M

机构：

[1] Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Lab Expt Anim Model Res, Obu, Aichi 4748522, Japan

[2] Univ Virginia, Cardiovasc Res Ctr, Dept Microbiol, Charlottesville, VA 22908 USA

[3] Univ Virginia, Cardiovasc Res Ctr, Dept Biomed Engn, Charlottesville, VA 22908 USA

[4] Natl Ctr Geriatr & Gerontol, Natl Inst Longev Sci, Dept Mech Aging, Obu, Aichi 4748522, Japan

来源：

FEBS LETTERS | 2005年 / 579卷 / 05期

关键词：

GEF; Rho; DOCK9; DOCK10; DOCK11; CZH2;

D O I：

10.1016/j.febslet.2005.01.006

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A novel superfamily of guanine nucleotide exchange factors for Rho GTPases includes DOCK180 and zizimin1. The zizimin subfamily includes three genes of which only zizimin1 has been cloned. We report here the cloning of zizimin2, identified in a screen for genes enriched in germinal center B cells. Zizimin2 and zizimin1 have similar primary structures and both proteins bound and activated Cdc42 but not the Cdc42-related proteins TC10 or TCL. Their tissue distributions are distinct, however, with zizimin2 expressed predominantly in lymphocytes and an opposite pattern for zizimin1. Zizimin3 was also analyzed and showed distinct GTPase specificity and tissue distribution. (C) 2005 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：1039 / 1046

页数：8

共 31 条

[1] Rho GTPases:: potential candidates for anticancer therapy [J].